Written by 10:38 am Basal Cell Carcinoma Views: 49

Written by James Moore Basal Cell Carcinoma

Enrollment Begins for Phase II Basal Cell Carcinoma Trial

basal cell carcinoma

According to a press release published in Healio, the company Medicus Pharma has begun enrolling participants for its Phase II clinical trial. This trial will evaluate the effectiveness of D-MNA, a needle microarray of doxorubicin, as a treatment for nodular basal cell carcinoma, a type of skin cancer.

The trial, designated SKNJCT-003, Patients will receive a 100 or 200 mg dose of D-MNA or a placebo.  The study will include a total of 60 participants. The primary outcome for the trial is total histological disappearance of basal cell carcinoma in the final excision. In the Phase I study, D-MNA was well tolerated at all evaluated dose levels. 

Basal cell carcinoma is one of the most common cancers, but noninvasive methods for treatment haven’t been successfully developed. If this trial has a positive outcome, however, the situation could change in the not-too-distant future. 

About Basal Cell Carcinoma

Basal cell carcinoma (BCC) is the most common type of skin cancer and is in fact the most common type of cancer diagnosed today. It typically looks like a risen area of skin that may be shiny or have a large number of blood vessels. It may also appear as a slow growing ulcer, though it generally isn’t painful. This cancer occurs on sun exposed areas and appears to be triggered by exposure to UV light for long periods. Other risk factors include light skin tone, radiation therapy, long-term arsenic exposure, and poor immune function. Symptoms include a shiny nodule on the skin, a reddish skin patch (similar to eczema), or an area resembling scar tissue. This cancer rarely spreads to distant areas or becomes life-threatening. Standard treatment includes surgical removal of the tumor, but more advanced approaches, such as chemotherapy, radiation therapy, immunotherapy, and photodynamic therapy, may be used in more severe cases. To learn more about basal cell carcinoma, click here

Editor’s Note: Get Involved

Cancer doesn’t discriminate. WHATNEXT and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a cancer journey to share, reach out here to learn more about how your voice can help spread awareness and inspire individuals from all walks of life.

(Visited 49 times, 1 visits today)

Last modified: September 6, 2024

Close